Department of Surgery, Mayo Clinic Florida, Jacksonville, Fla.
Department of Cardiology, Mayo Clinic Florida, Jacksonville, Fla.
J Thorac Cardiovasc Surg. 2014 Jun;147(6):1972-7, 1977.e1. doi: 10.1016/j.jtcvs.2014.02.013. Epub 2014 Feb 12.
The aim of our study was to identify preoperative risk factors affecting overall survival after cardiac retransplantation (ReTX) in a contemporary era.
The United Network for Organ Sharing database was used to identify patients undergoing ReTX between 1995 and 2012. Of the total 28,464 primary transplants performed, 987 (3.5%) were retransplants. The primary outcome investigated was overall survival. The influence of preoperative donor and recipient characteristics on survival were then tested with univariate logistic regression and multivariate Cox regression models.
Of 987 patients who underwent ReTX, median survival was 9 years. Estimated survival at 1, 3, 5, 10, and 15 years following retransplant was 80% (95% confidence interval [CI], 78%-83%), 70% (95% CI, 67%-73%), 64% (95% CI, 61%-67%), 47% (95% CI, 43%-51%), and 30% (95% CI, 25%-37%), respectively. Clinical predictors of survival using multivariable analysis included donor age (relative risk [RR], 1.14; P = .004), ischemic time > 4 hours (RR, 1.48; P = .004); preoperative support with extracorporeal membrane oxygenator (RR, 3.91; P < .001), and the time between previous and current transplant (P = .004). Patients with ReTX have 1.27 times higher relative risk of death compared with patients undergoing primary transplant only (RR, 1.27; 95% CI, 1.13-1.42; P < .001).
Patients who undergo cardiac ReTX can expect to have a 1-year survival less than a patient undergoing primary transplant with an acceptable median overall survival. Both donor and recipient preoperative factors contribute to overall survival following cardiac ReTx. Donor characteristics include age of the donor and ischemic time. Recipient factors include the need for extracorporeal membrane oxygenator and the number of days between the first and second transplant. Optimal survival following cardiac ReTX can best be predicted by choosing patients who are farther out from their initial transplant, not dependent upon preoperative extracorporeal support, and by choosing donor hearts younger in age and those likely to have shorter ischemic times.
本研究旨在确定影响心脏再次移植(ReTX)后总生存率的术前危险因素。
使用美国器官共享网络数据库(United Network for Organ Sharing database)确定 1995 年至 2012 年间进行 ReTX 的患者。在总共进行的 28464 例初次移植中,有 987 例(3.5%)为再次移植。主要研究结果是总生存率。然后使用单变量逻辑回归和多变量 Cox 回归模型测试术前供体和受体特征对生存率的影响。
在 987 例接受 ReTX 的患者中,中位生存时间为 9 年。估计再次移植后 1、3、5、10 和 15 年的生存率分别为 80%(95%置信区间[CI],78%-83%)、70%(95%CI,67%-73%)、64%(95%CI,61%-67%)、47%(95%CI,43%-51%)和 30%(95%CI,25%-37%)。多变量分析显示,影响生存的临床预测因素包括供体年龄(相对风险[RR],1.14;P=.004)、缺血时间>4 小时(RR,1.48;P=.004)、体外膜肺氧合(ECMO)术前支持(RR,3.91;P <.001)以及前次和本次移植之间的时间(P=.004)。与仅接受初次移植的患者相比,接受 ReTX 的患者死亡的相对风险高 1.27 倍(RR,1.27;95%CI,1.13-1.42;P <.001)。
接受心脏 ReTX 的患者 1 年生存率预计低于接受初次移植的患者,中位总生存率尚可接受。供体和受体术前因素均影响心脏再次移植后的总生存率。供体特征包括供体年龄和缺血时间。受体因素包括是否需要体外膜肺氧合以及首次和第二次移植之间的天数。通过选择距离初次移植时间较长、术前无需体外支持且供体心脏较年轻、缺血时间较短的患者,可最佳预测心脏 ReTX 后的最佳生存率。